Supplementary Table 8).
We identified proportionately more PLCG1 mutations in the extension cohort (Supplementary Table 9 ). The most frequently mutated genes in the combined cohort were TP53 (24%), PLCG1 (18%), CARD11 (15%), ARID1A (10%), FAS (10%), CCR4 (7%), RHOA (7%) and TNFRSF1B (6%) (Fig. 2) .
TP53 was the most frequently mutated gene (Fig. 2a) . In ten of 11 patients in the discovery cohort, point mutations were accompanied by copy number losses (del17p). In the discovery cohort, over onehalf (6/11) of TP53 mutations were located at canonical splice sites. The mutant alleles of all TP53 splicing mutations were expressed, and changes in TP53 exon usage accompanied four of five splice-site mutations (data not shown).
The chemokine receptor encoded by CCR4 is important for T cell migration into skin 30, 31 . Overexpression of CCR4 was reported in Sézary syndrome 32 , and, as a result, therapy targeting CCR4 is underway, with promising early results in patients with CTCL 32, 33 . Recently, gain-of-function CCR4 mutations mapping to the C terminus of the protein were reported in 26% of cases of adult T cell leukemia/ lymphoma (ATLL), a disease caused by human T cell lymphotropic virus-1 (HTLV-1) 34 that, like Sézary syndrome, also exhibits skinhoming pathophysiology. In our cohort, 7% of the patients with Sézary syndrome harbored CCR4 somatic mutations, and all of the encoded changes were located in the C terminus of the protein, including recurrent p.Tyr331* and p.Gln330* alterations and alterations at three additional sites not previously reported (Fig. 2a) . All CCR4 mutations were either nonsense or frameshift. Moreover, the CCR4 mutations were heterozygous and expressed at significantly higher levels than in normal controls (P < 0.0373; Fig. 2b ), consistent with a functional role as activating mutations.
CARD11, mutated in 15% of patients with Sézary syndrome (Figs. 1a and 2a), encodes a multidomain adaptor protein required for TCRmediated activation of nuclear factor (NF)-κB signaling and is a critical regulator of both T and B cell activation and function [35] [36] [37] . Activating CARD11 mutations were reported in 9.6% of diffuse large B cell lymphomas (DLBCLs), with virtually all mutations affecting the two coiled-coil domains 38, 39 , which are located at the N terminus of the protein (Fig. 2a) . Introduction of CARD11 mutants in which either coiled-coil domain was mutated resulted in constitutive NF-κB activation in lines of both T and B cell origin 39 . In our combined cohort, we identified 16 CARD11 mutations, one-half of which mapped to the second coiled-coil domain. The remaining mutations mapped to a new hotspot located adjacent to the N-terminal edge of the PDZ domain (Fig. 2a) . All the mutated positions in this new hotspot correspond to highly conserved residues (Supplementary Fig. 6 ). Additionally, we detected a CARD11-PIK3R3 fusion (Supplementary Table 10 ) in a patient with wild-type CARD11, with the encoded fusion protein including the new hotspot region but not the N-terminal coiled-coil domains. CARD11 expression was significantly increased in patients with either wild-type or mutant CARD11, including in the patient with the fusion transcript, in comparison to expression in healthy donors (Fig. 2b) . These data provide strong evidence of a role for CARD11 in Sézary syndrome; therefore, therapies targeting CARD11 signaling could benefit patients, as was previously suggested for CARD11-mutated DLBCL 39 .
PLCG1, a key mediator in TCR signaling (Fig. 3b) , was recently found to be mutated in 27% of patients with mycosis fungoides and 9% of patients with Sézary syndrome 21 . We identified five PLCG1 mutations in the discovery cohort (Fig. 2a) , but none were at reported sites. In the extension cohort, the frequency of PLCG1 mutations increased to 21% (14/68) from 14% (5/37) in the original cohort, although the frequencies for the two cohorts were not significantly Table 9 ). In addition to the reported hotspot alteration p.Ser345Phe, we identified a new hotspot substitution (p.Arg48Trp) in the N terminus of the protein ( Fig. 2a and Supplementary Fig. 7) . Interestingly, the frequency of the PLCG1 mutation encoding p.Arg48Trp was significantly higher in patients with a previous history of mycosis fungoides (15% in comparison to 3%, P = 0.041), suggesting the possibility that PLCG1 may have a role in the transformation of mycosis fungoides into Sézary syndrome. Figure 1 Somatic genomic alterations identified in Sézary syndrome. (a) Top, somatic mutation rates estimated by whole-exome sequencing. Middle, somatic mutations displayed by patient (columns) and by gene (rows), including point mutations, somatic copy number alterations and recurrent fusion transcripts. The top rows show patient ID followed by clinical and histopathological data. Race: W, white; AA, African American; H, Hispanic; AI, American Indian. Sézary syndrome (SS) origin: Pre-MF, previous history of mycosis fungoides. LCT, large cell transformation. The number of months lived after disease diagnosis to last clinical visit or death is indicated together with vital status. Annotation indicating expression in RNA-seq data has been added for all missense and splicing mutations: a star indicates that the mutant allele was observed in the corresponding transcripts from RNA-seq data. Only genes that met at least one of the following criteria were listed: significantly mutated genes (MutSigCV, false discovery rate (FDR) <0.1; BCMsig, total points ≥9); genes with significant focal copy number alterations (P < 0.05); genes involved in in-frame fusions in ≥2 patients; cancer-related or biologically important genes (overlap with the Cancer Gene Census or MSigDB database; see URLs); and genes with 2 or more nonsense, frameshift or expressed missense mutations that were replicated in the extension cohort. LOH, loss of heterozygosity. Bottom, the mutational spectrum. DNM, dinucleotide mutation; indel, small insertion or deletion. Samples for which RNA-seq ( §) or SNP array analysis ( ¶) was not performed owing to a lack of materials are indicated. 
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Other somatically mutated genes determined to be likely drivers were ARID1A, FAS, TNFRSF1B and RHOA. Recurrent mutation of these genes was replicated in the extension cohort ( Supplementary Fig. 5 and Supplementary Table 9 ). Most of the ARID1A mutations were inactivating, consistent with the usual pattern of ARID1A mutations observed in other cancers. Likewise, most of the FAS mutations were inactivating. Given the reported downregulation of FAS, a pro-apoptotic death receptor 40, 41 , the occurrence of inactivating FAS mutations in seven patients reinforces the putative role of these mutations in aiding the survival of malignant cells. TNFRSF1B mutation encoding p.Thr377Ile was recently reported in 5% of patients with CTCL 42 . Expression of TNFR2 with the corresponding protein alteration in T cells leads to enhanced non-canonical NF-κB signaling 42 . Independently, we identified six mutations in this gene: one of them encoded the p.Thr377Ile substitution and the other five were clustered together, indicating a new mutation hotspot ( Supplementary Fig. 5 ). Finally, seven missense mutations with likely functional impact were observed in RHOA, which encodes a small GTPase that acts to regulate the actin cytoskeleton and cell division.
Somatic copy number alterations
Somatic DNA copy number analysis identified frequent genomic gains and losses (Fig. 2c) . We found CDKN2A focal deletion in 58% of the patients, in comparison to the frequency of about 40% previously reported 19 . CDKN2A expression was significantly decreased in patients with homozygous deletions (Fig. 2d) , as expected.
The most frequent new event in our discovery cohort was a 0.6-Mb focal deletion at 10p11.23, including ZEB1 and ZNF438, observed in 56% of the patients (Fig. 2c) . Of the two genes, only ZEB1 showed expression in proportion to copy number ( Fig. 2d ) in comparison to patients with diploid ZEB1 (P < 0.001), suggesting that ZEB1 may be the target of selection within this focal deletion. Recently, this focal deletion was independently reported by Choi et al. 43 . ZEB1, also known as T cell transcription factor 8, is a zinc-finger transcriptional repressor that harbors two independent repressor domains; the N-terminal one blocks the activity of hematopoietic transcription factors such as ETS and c-MYB and regulates hematopoietic differentiation 44 . ZEB1 was suggested to be critical for early T cell development 45 and has a role in enhancing transforming growth factor-β1 (TGF-β1) signaling by binding phosphorylated SMAD3 and SMAD7 (ref. 46) . ZEB1 downregulation contributes to resistance to TGF-β1-mediated growth suppression in ATLL-derived cell lines 46, 47 . Loss of ZEB1 may have a similar role in the pathogenesis of Sézary syndrome.
Hemizygous deletion of 1p36.1 (in 33% of patients) encompassed six genes, including ARID1A and RPS6KA1. Expression levels of both ARID1A and RPS6KA1 decreased and correlated significantly with copy number status (Fig. 2d) , suggesting selection operating on these two genes. As mentioned above, six patients in our combined cohort harbored inactivating mutations in ARID1A (Supplementary Fig. 5 ), consistent with the function of ARID1A as an epigenetic tumor suppressor. Although ARID1A is best known as a component of the SWI/SNF chromatin-remodeling complex, recent functional studies suggested a role for ARID1A in cell cycle checkpoint machinery, possibly through p53-and/or Rb-dependent signaling cascades 48 . ARID1A is required for cell cycle exit, as cell cycle arrest is delayed in the absence of functional ARID1A 49 . RPS6KA1 is a serine/threonine kinase that has a pivotal role in growth factor-induced delay in the G2/M transition and is required to maintain genomic integrity during growth factor stimulation 50 . npg Thus, we place these two genes in an ensemble of mutated genes in the dysregulated replication cycle in Sézary cells (Fig. 3a) .
Finally, we identified focal deletion of 2q37.3 involving PDCD1 and five other genes in 36% of patients (Fig. 2c) . Subjects with 2q37.3 deletion tended to have a worse prognosis (P = 0.05; Supplementary  Fig. 8 ). PDCD1 (encoding programmed death 1; also named PD-1) is expressed on activated T cells and transduces a negative signal that suppresses T cell function 51 . PDCD1 is suggested to be a promising immunotherapeutic target in cancer because blockage of PDCD1 and its ligands can enhance the functioning of cytotoxic T cells 52 . However, we observed no correlation between expression and copy number for PDCD1 or any other genes in this region in the current cohort (Supplementary Fig. 9 ).
Fusion transcripts and differentially expressed genes
We identified 41 in-frame fusion transcripts by RNA-seq (Supplementary Table 10 ). For 29 fusion transcripts with total RNA available, we performed RT-PCR (Supplementary Table 11) , sequenced the RT-PCR products and successfully validated all of them. In addition to the aforementioned CARD11-PIK3R3 fusion, we observed CD28-CTLA4/ICOS and IKZF2-GLI2 fusions. CD28 is essential for T cell proliferation and survival. Independently, fusion of CD28 to CTLA4 was recently reported in CTCL 42 . IKZF2 regulates lymphocyte development. Overall, gene-gene fusions appear to be relatively rare in the pathogenesis of Sézary syndrome.
To identify differentially expressed genes, we performed an unbiased analysis of the expression data for all detectable transcripts (>40,000). A total of 345 transcripts were significantly upregulated in our cohort in comparison to expression in healthy donors (Supplementary Table 12) . Gene set enrichment analysis of these upregulated genes suggested significant enrichment of only a few canonical pathways (Supplementary Table 13 ), among which were cell cycle control, regulation of immune system, MYC transcriptional activation and chemokine signaling.
Among these 345 genes, several interleukins, interleukin receptors, CD molecules and chemokines that are required for T cell development and function were strongly upregulated, including IL32, IL2RG, CD3G, CD27, CCR4 and CCR8 (Table 1) . IL2RG, encoding the interleukin (IL)-2 receptor common γ chain, was highly expressed in all patients. IL-2Rγ heterodimerizes with several other receptors and may transmit enhanced cytokine signaling to Sézary cells. IL32 was the most upregulated chemokine (Fig. 4a) and was strongly upregulated in all but one patient, who had a low level of Sézary cells. Interestingly, IL32 expression levels were positively correlated with those of IL2RG and CARD11 (Supplementary Fig. 10 ). IL-32 is a proinflammatory cytokine expressed by activated T cells and natural killer (NK) cells with an important role in T cell communication, tumorigenesis and autoimmune disease 53 . IL-32 accelerates the proliferation of CTCL cell lines through mitogen-activated protein kinase (MAPK)-and NF-κB-mediated signaling 53 . A high level of IL32 expression in skin lesions from patients with mycosis fungoides was reported to correlate with disease activity 53, 54 .
We examined IL-32 protein expression in CTCL cell lines and tumor cells from a subset of patients with Sézary syndrome. IL-32α was not detectable in the serum of patients with Sézary syndrome or the cell culture supernatant of any cell lines (data not shown), suggesting that IL-32α might function intracellularly rather than intercellularly in the context of Sézary cells. Immunoblot analysis employing a purified monoclonal antibody to human IL-32, which has been shown to bind to all isoforms of IL-32 (ref. 55) , showed a single strong band at 24 kDa, indicative of IL-32β translation in all cell lines (Fig. 4b) . IL-32 protein expression in patient-derived cells was more heterogeneous, with expression of both the α and β isoforms in some patients (Fig. 4c) . Overall, protein expression was correlated with mRNA expression and the density of Sézary cells in the blood. These data support the possibility that IL-32 is involved in an autocrine signaling loop stimulating growth of Sézary cells, as suggested by Suga et al. 53 .
Dysregulated signaling pathways
Our integrated genomic analyses identified frequent alterations primarily in three oncogenic pathways (Supplementary Table 14) : epigenetic regulation (95%), TCR signaling (84%) and cell cycle control (78%). Notably, we identified frequent alterations in genes involved in cell 
npg
A r t i c l e s cycle control, especially genes that regulate the G1/S and G2/M checkpoints (Fig. 3a) . Multiple genes were recurrently altered at a high frequency, including the aforementioned TP53, CDKN2A, ARID1A and RPS6KA1 genes, suggesting that loss of mitotic checkpoint control might be an important contributor to the high rate of genomic instability observed in patients with Sézary syndrome. Additionally, we identified somatic alterations in TCR signaling in 84% of cases (Fig. 3b) . TCR signaling in response to antigen recognition has a critical role in the adaptive immune response. Recurrent alterations were identified in CARD11, PLCG1, LAT, RAC2, PRKCQ, CD28 and genes that encode calcium channel subunits. Finally, although epigenetic regulation was most frequently altered, the majority of the genes involved were mutated only once each. All eight classes of epigenetic genes 56 were somatically altered across the cohort, with the highest frequency (66%) of alterations among the histone writers (Supplementary Tables 15 and 16) .
The TCR repertoire
The orderly rearrangement and assembly of TCR genes during T cell development creates a polyclonal TCR repertoire that is highly diverse IL10  IL11  IL10RA  IL11RA  IL12A  IL12B  IL12RB1  IL12RB2  IL13  IL15  IL16  IL17A  IL17B  IL17C  IL17D  IL17F  IL17RA  IL18  IL18BP  IL18R1  IL18RAP  IL19  IL1A  IL1B  IL1F10  IL1R1  IL1R2  IL1RAP  IL1RAP  IL1RAPL1  IL1RAPL2  IL1RL1  IL1RL2  IL1RN  IL2  IL20  IL20RA  IL20RB  IL21  IL21-AS1  IL21R  IL21R-AS1  IL22  IL23A  IL23R  IL24  IL25  IL26  IL27  IL27RA  IL2RA  IL2RB  IL3  IL31  IL32  IL33  IL34  IL36A  IL36B  IL36G  IL36RN  IL37  IL4  IL4I1  IL4R  IL5  IL5RA  IL6  IL6R  IL6RP1  IL6ST  IL6STP1  IL7R  IL7  IL8  IL9  IL3RA  IL31RA  IL22RA1  IL22RA2  IL20RB-AS1  IL2RG  IL17RB  IL17RC  IL17RD  IL17RE  IL17REL  IL15RA  IL13RA1  IL13RA2 Table 17 ), in comparison to the 67% of patients determined to have such clones by flow cytometry analysis of TCR Vβ using fluorescencelabeled monoclonal antibodies. Our analysis identified varied patterns in the dominant Vβ and Vα receptors. We detected monoclonal, biclonal and polyclonal TCR Vβ in 56%, 22% and 22% of patients and monoclonal, biclonal and polyclonal TCR Vα in 66%, 22% and 12% of patients, respectively (Supplementary Table 17 ). The apparent polyclonal patterns probably represent patients whose V-region DNA segment is not present in the reference genome. The most frequent clonally expanded TCR Vα gene was TRAV27, followed by TRAV9-2. The most frequent clonally expanded TCR Vβ gene was TRBV20-1, followed by TRBV7-3 ( Supplementary Fig. 11 ). TRBV20-1 is associated with S. aureus superantigen stimulation 58 , a common feature of Sézary syndrome; this finding is consistent with the antigen stimulation theory of CTCL 59 .
Correlation and survival analysis
Finally, our correlation and survival analyses confirmed that large cell transformation (LCT) and African ancestry were associated with worse prognosis 9, 60 (Fig. 5a) , which was also replicated in the extension cohort (Supplementary Fig. 12 ). TP53 mutation and 2q37.3 focal deletion were significantly enriched in patients with LCT (Fig. 5b) . Interestingly, we found that prevalence of UVB signature was significantly lower in African-American patients, whereas IL32 expression was significantly higher (Fig. 5c) . Overexpression of IL32 in African-American patients with worse prognosis further suggests a connection between IL32 and the pathophysiology of Sézary syndrome. Our survival analysis also suggested a trend toward worse prognosis in patients with CCR4 alteration, CDKN2A or 2q37.3 deletion (Supplementary Fig. 8 ).
DISCUSSION
To gain more insight into the genomic basis of Sézary syndrome, we assessed somatic mutation, DNA copy number and gene expression profiles in 37 patients. In addition to somatic alterations in established Sézary syndrome-associated genes such as TP53 and CDKN2A, we identified recurrent mutations and/or focal deletions in CARD11, CCR4, PLCG1, ARID1A and ZEB1, among other genes. Several somatic alterations are reported to specifically affect T cell signaling and differentiation. These data, coupled with overexpression of IL32 and IL2RG, lend mechanistic insights into the nature of Sézary syndrome pathogenesis and suggest avenues for development of targeted therapies. Notably, this study has drawn a number of parallels, through shared molecular features, to other malignancies of both B and T cell origin. The activating CCR4 mutations first reported in patients with ATLL are in common with the mutations found in our patients with Sézary syndrome and highlight the importance of CCR4 in pathogenesis and targeted therapy of both lymphomas. Alteration of the coiled-coil domain of CARD11 that potentiates NF-κB signaling in B cells has been recognized as a potential therapeutic target in DLBCL. To these markers, Sézary syndrome adds IL-32 as possible constituents of an autocrine signaling network, which could become targets specific to Sézary syndrome.
Important to the etiology of the disease is a description of the cell of origin of this malignancy, and both T CM and T RM cells have been proposed 29 . The surprising finding of a UVB mutational signature in 30% of the patients is strong evidence that the malignant clonal population arose from a cell that spent substantial time in the superficial layers of the skin, consistent with a T RM origin.
In conclusion, the genomic profiling presented here not only adds to understanding of genetic driver mutations and T cell signaling, but also to the pathophysiology of Sézary syndrome, and identifies new targets and pathways for developing more effective therapies. 
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METHODS
Methods and any associated references are available in the online version of the paper. Isolation of CD4 + cells. Peripheral blood was collected before therapy from all patients with Sézary syndrome using BD Vacutainer Cell Preparation tubes. PBMCs were then isolated from granulocytes. CD4 + T cells were separated from CD4 − lymphocytes using the CD4 + T Cell Isolation kit (Miltenyi Biotec). The purity and Vβ usage of CD3 + CD4 + CD26 − T cells were confirmed by flow cytometry; all CD4 + T cell samples had a purity of >90%. The CD4 − cells were also collected, from which DNA was isolated and used as a second matched control for the identification of somatic mutations. Our analysis suggested contamination from Sézary cells in the CD4 − cell population (data not shown), and matched fibroblast DNA was thus used as the germline control for somatic mutation and copy number analyses.
Skin punch biopsy and fibroblast cell culture. A 6-mm biopsy of normal skin from the inner arm was performed for all patients. Explanted fibroblasts were grown and maintained in DMEM supplemented with non-essential amino acids, 1% penicillin/streptomycin, 1% HEPES, 1% sodium pyruvate and 10% FBS (DMEM-FBS) at 37 °C in humidified air containing 5% CO 2 . Fibroblasts were subcultured using trypsin-EDTA. DNA and total RNA were extracted at passage 3 to 4 (ref. 61 ).
DNA and RNA extraction. For all samples, about 5 × 10 6 cells were collected, and genomic DNA and total RNA were extracted simultaneously using the All Prep DNA/RNA/Protein Mini kit (Qiagen) following the manufacturer's protocol.
Whole-exome sequencing library preparation, exome capture and sequencing. DNA samples were constructed into Illumina paired-end precapture libraries as previously described 25 , with minor modifications. Briefly, 0.5 µg of DNA was sheared into fragments of 200-300 bp in length in a Covaris plate with E210 system, followed by end repair, A-tailing and ligation with Illumina multiplexing paired-end adaptors. Precapture ligation-mediated PCR (LM-PCR) was performed using Library Amplification ReadyMix containing KAPA HiFi DNA polymerase (Kapa Biosystems, KK2612). Universal primers IMUX-P1.0 and IMUX-P3.0 were used in PCR amplification. For a subset of the libraries constructed in this study, these molecular barcodes were introduced at the PCR step using Phusion High-Fidelity PCR Supermix (2×) (New England BioLabs, M0531L). Purification was performed with Agencourt AMPure XP beads after enzymatic reactions. After the final AMPure XP bead purification, the quantity and size distributions of the precapture LM-PCR products were determined using the LabChip GX electrophoresis system (PerkinElmer) and gel analysis using AlphaView SA v3.4 software.
For the hybridization step, four such precapture libraries were pooled together. The pooled libraries were then hybridized in solution to the HGSC VCRome 2.1 design. For post-capture LM-PCR amplification, either matching KAPA HiFi DNA polymerase or Phusion High-Fidelity PCR Supermix (2×) was used. After the final AMPure XP bead purification, the quantity and size distributions of the capture library were analyzed using the Caliper LabChip GX electrophoresis system. The efficiency of capture was evaluated by performing a quantitative PCR-based quality check on the enrichment level of four standard NimbleGen control loci. All sequencing runs were performed in paired-end mode on the Illumina HiSeq 2000 platform.
Whole-exome sequencing data processing, mutation calling and filtering. Whole-exome sequencing data processing, mutation calling and annotation were performed using the standard pipelines established at HGSC as described previously 25 . A stepwise filtering approach was performed to identify highconfidence somatic mutations. Briefly, we first applied quality filters, and only variants meeting the following criteria were selected: (i) total read coverage in the tumor and its matched control sample ≥5 and ≥2, respectively; (ii) variant read coverage in the tumor ≥2; (iii) variant allele fraction (VAF) in the tumor ≥0.04; and (iv) ratio of VAF in the normal sample and its corresponding tumor sample ≤0.15. Second, germline filters were applied, and any variants observed in the germline MAF file of the cohort were removed. After this step, common SNPs were filtered out using dbSNP139. Finally, all variants left were visualized in the Integrative Genomics Viewer (IGV; see URLs), and the mapping quality and uniqueness of the supporting reads were assessed using BLAT (see URLs). Variants with ambiguous mapping and poor mapping quality were removed from the list.
Mutation significance. The statistical significance of the mutation frequency in each gene was determined using the MutSigCV algorithm (v1.4) 62 and our in-house BCMsig method. For MutSigCV analysis, a P value of <0.05 and a q value (FDR) of <0.1 were considered statistically significant. Given that application of MutSigCV to our data set identified only two significantly mutated genes, we employed an alternative approach that is more sensitive to somatic mutation identification for smaller tumor data sets. BCMsig is a simple binary algorithm that borrows elements from MutSigCV but also incorporates other parameters, such as RNA expression data in both normal T cells and Sézary cells, the cancer mutation literature and the likely functional impact of individual mutations. Analysis of the final somatic mutation file from the discovery cohort identified 480 genes that had at least two non-silent somatic mutations. For each of these genes, 13 parameters were analyzed and given scores of −1, 0 or +1, as indicated in rows 1-4 of Supplementary Table 7 .
The scores for the 13 parameters were summed to yield the total score for each gene. All genes with a total score equal to or greater than that of TP53 (9 points) were considered to be significantly mutated.
Mutation signatures. Non-negative matrix factorization (NMF) was used to evaluate the mutation signatures associated with Sézary cells, of which a set of 21 were available. Mutation data were transformed into a data matrix V 96,n by normalizing and grouping mutations for each of the 16 mutation contexts (and six possible base changes) for each of n subjects. Solutions were generated by solving the equation V = W × H + E, where W 96,21 is the basis matrix of the NMF solution (K.R.C. and D.A.W., unpublished data) and H 21,n is the coefficient matrix for the set of patients with Sézary syndrome, subject to minimizing the squared error (E). H was taken as the set of overall signature exposure values, commonly referred to as the coefficient matrix. H can be taken to mean the number of mutations in a patient's sample attributable to each signature (Supplementary Fig. 4a,b) . H was also scaled such that each column of H summed to 1 to represent the proportion of mutations attributable to each signature (Fig. 1b) . Both scaled and unscaled exposure values were merged with clinical, genomic and transcriptomic data for further analysis.
Mutation validation and mutation prevalence. We selected 35 frequently altered genes and designed a custom NimbleGen array (target size of ~200 kb; Supplementary Table 4) for mutation validation and mutation frequency screening. A total of 142 DNA samples were collected from patients in our combined cohort. We used 0.1-0.5 µg of DNA per sample for the validation study.
The basic Illumina library preparation protocol and the regents used were identical to those for whole-exome sequencing except that, for validation, a set of 96 molecular barcodes was used to allow high-density multiplexing. The capture enrichment protocol was also the same as described earlier for whole-exome sequencing, with the following modifications: for capture, four pools with 35-36 libraries/pool were prepared and hybridized in solution to the custom capture design. Overnight hybridization at 56 °C was carried out instead of hybridization for 3 d at 47 °C, as done for whole-exome sequencing. The steps following enrichment were also similar: the four enriched pools were pooled into two groups (with 70 and 72 libraries/pool) and sequenced on two lanes of a HiSeq 2500 instrument. On average, 500 Mb of uniquely mapped sequence data were generated across the target region and the targeted bases were covered to 1,226×.
For paired samples, the workflow of data processing was similar to that for whole-exome sequencing. A mutation was considered valid if five or more supporting reads were detected. For tumor-only samples, a stepwise filtering npg approach was applied to identify high-confidence potential somatic mutations. Briefly, only non-silent mutations with ≥5 supporting reads and a VAF of ≥0.01 were selected, and common SNPs were eliminated using the dbSNP139 database. The list was further cleaned by removing variants present in any of the fibroblast controls. Finally, all remaining mutations were visualized in IGV, and the mapping quality and uniqueness of the supporting reads were assessed using BLAT. Variants with ambiguous mapping or poor mapping quality were removed from the list.
RNA-seq library construction, sequencing and quality control. High-quality total RNA (RNA integrity number (RIN) >7) was used to prepare strandspecific, poly(A) + Illumina RNA-seq libraries. To monitor sample and process variability, in addition to sequence metrics, RNA developed by the External RNA Controls Consortium (ERCC), which consists of a mixture of 92 poly(A) + RNA transcripts, was also added to total RNA at the beginning of library preparation. Briefly, poly(A) + mRNA was extracted from 1 µg of total RNA using oligo(dT) 25 Dynabeads (Life Technologies, 61002) followed by fragmentation, first-strand cDNA synthesis, second-strand cDNA synthesis, end repair, A-tailing, ligation with Illumina paired-end adaptors and digestion with 10 units of uracil-DNA glycosylase (New England BioLabs, M0280L). Amplification of the libraries was performed with 13 or 14 PCR cycles using Phusion High-Fidelity PCR Master Mix; 12 molecular barcodes of 6 bp in length were also incorporated during this PCR amplification. The cDNA was purified with Agencourt AMPure XP beads after each enzymatic reaction and after quantification using the Agilent Bioanalyzer 2100 DNA Chip 7500 (5067-1506). Libraries were pooled in equimolar amounts (2-5 libraries/pool). The library pools were then loaded onto a HiSeq flow cell lane, and, following amplification with Illumina's cBot cluster generation system, sequencing runs were performed in paired-end mode (2 × 101-bp reads) using the Illumina HiSeq 2000 and HiSeq 2500 platforms. The data generated were processed through an automated RNA-seq pipeline built for quality control and the analysis of gene fusions and expression. RNA-SeQC (v1.1.7) 63 was applied to generate a series of quality control metrics for the RNA-seq data.
Expression quantification. The FASTQ data generated by the production pipeline were mapped to the human genome (both hg19 and known splice junction loci) using the STAR RNA-seq aligner (v2.3.1) 64 . The human genome and gene models (GRCh37.69) were downloaded from Ensembl (see URLs). Transcripts were then assembled with Cufflinks (v2.1.1) 65 , and the expression level of each gene was calculated and normalized.
Gene fusion detection and filtering. To identify gene fusion transcripts, RNA-seq reads in FASTQ format were aligned to the human genome using the deFuse algorithm (v0.6.1) 66 . DeFuse was run with default parameters, and a probability score was assigned to each candidate with the DeFuse classifier. The candidate gene fusion transcripts were filtered step by step to identify high-confidence fusion events. Briefly, fusion transcripts with preservation of the ORF and with a probability score of >0.3 were selected. The mapping uniqueness of each fusion contig was assessed using BLAT, and fusions with ambiguous mapping were removed. The supporting reads for each fusion event were then visualized in IGV and remapped using BLAT. Similarly, only reads correctly mapped to the annotated positions were counted as supporting reads. Finally, fusion transcripts with three or more supporting reads were selected for validation.
Fusion gene validation. Validation of fusion transcripts was carried out via PCR amplification of first-strand cDNA followed by Illumina MiSeq sequencing of amplicon pools. Validation primers (Supplementary Table 11) were designed using the Primer3 program (see URLs). For each validation event, one oligonucleotide matching each end of the splitter was selected as forward and reverse primers to generate an amplicon containing the breakpoint of the fusion RNA. Briefly, 200 ng of total RNA was used to prepare first-strand cDNA, and the first-strand cDNA was amplified on an Eppendorf Mastercycler ep384 with Takara LA Taq DNA polymerase, Hot-Start version (RR042, Clontech). PCR products were examined and further purified. Amplicons with low yield were subjected to another round of the PCR program using 2% of the PCR product from the first round as template. Purified PCR products were pooled in equimolar amounts for Illumina library construction. Two pools of 29 amplicons were sequenced on a MiSeq sequencer.
Sequencing reads were aligned to the human genome as described above for RNA-seq data. For each fusion event, the corresponding validation BAM file was loaded to and visualized in IGV. The sequences of the supporting reads were extracted and remapped using BLAT to confirm fusion breakpoints.
Mutation cross-validation with RNA-seq data. RNA-seq data were also used to cross-validate the somatic mutations identified by whole-exome sequencing. For each somatic mutation reported by whole-exome sequencing, SAMtools (v0.1.8) 67 was used to count the read coverage for the variant and reference alleles in corresponding RNA-seq BAM files. A minimum of one high-quality supporting read was required to define a validated mutation. The validation results placed variants into one of four different classes: (i) validated with VAF >5%; (ii) validated with VAF <5%; (iii) mutant allele not expressed, if the mutation site was well covered but no mutant allele was detected; and (iv) no information, if no reads were mapped to the particular mutation site or gene.
TCR clonality analysis. GENCODE Genes (v18; see URLs) was used for annotation of the TCR loci. igvtools (see URLs) was used to extract the base coverage of the corresponding TCR loci from RNA-seq BAM files for all samples. Wiggle files were generated for each sample and loaded into IGV for further analysis. The read scale was adjusted between the tumor and control samples for better visualization.
SNP arrays and DNA copy number. Infinium SNP array assays were performed with Illumina Human OmniExpress12 v1-1 BeadChips (WG-312-1120). In brief, 200 ng of genomic DNA was denatured, and isothermal wholegenome amplification was performed. The amplified DNA was enzymatically fragmented and hybridized to the BeadChip for 16-24 h at 48 °C in a hybridization oven. Twelve samples were processed in parallel on each BeadChip. A series of washing steps was performed to remove unhybridized and non-specifically hybridized DNA fragments from the BeadChip, followed by allele-specific single-base extension and multilayer staining. Coated BeadChips were imaged using the Illumina iScan system. SNP calls were collected using Illumina GenomeStudio v2011.1 software. The cutoff for the SNP call rate was set at 0.9, and data from samples passing this metric were used for further analyses.
For improved CNV analysis, B-allele frequencies (BAFs) were calculated and log 2 R ratios (LRRs) were extracted after reclustering the raw data by applying the GenomeStudio clustering algorithms. BAF and LRR data were then loaded into Nexus Copy Number v7.5 (BioDiscovery) to identify somatic DNA copy number alterations in Sézary syndrome. Systematic correction was applied to all samples, with parameter settings refined for the Illumina OmniExpress platform to correct GC content-related data waviness. The SNP-FASST2 segmentation algorithm was selected, and matched paired analysis was performed following the designer's manual. Significant peaks were selected with a P value cutoff of 0.05 and an aggregating frequency cutoff of 20%.
IL-32 ELISA. The human CTCL cell lines HH, Hut78 and MJ were purchased from the American Type Culture Collection (ATCC). Other cell lines were kind gifts from I. Litvinov (McGill University). Cells were grown at 0.2-1.0 × 10 6 cells/ml in HEPES-buffered RPMI 1640 medium as previously described 12 . Cell culture supernatants were collected on day 3 after the media were refreshed. Whole blood from patients (8 ml) was collected into a red-topped tube without additives, kept at room temperature for 30 min and then centrifuged for 10 min at 1,000g. The serum layer was then removed and aliquotted into small tubes and stored at −80 °C until use. The five normal human serum samples were purchased from different vendors, aliquotted into small tubes and stored at −80 °C until use.
Soluble IL-32α in cell culture supernatants and human sera was measured using Human IL-32α ELISA MAX Deluxe (BioLegend). Briefly, the day before the assay, 100 µl of a 1:200 dilution of the capture antibody coating solution was added to each well, and the plate was incubated overnight at 4 °C. Washing was performed immediately after each of the following steps to remove nonspecific antibody binding. First, 200 µl of 1× Assay Diluent A was added to each well, and the plate was incubated at room temperature for 1 h to block npg non-specific binding. After that, 100 µl of standards or samples was added to each well, and the plate was incubated at room temperature for 2 h. The human IL-32α standard concentrations used were 500, 250, 125, 62.5, 31.3, 15.6 and 7.8 pg/ml. 1× Assay Diluent A served as the zero standard (0 pg/ml). All standards were run in duplicate, and all samples were run in triplicate. After washing, 100 µl of a 1:200 dilution of detection antibody solution was added to each well, and the plate was incubated at room temperature for 1 h. Next, 100 µl of a 1:1,000 dilution of Avidin-HRP solution was added to each well, and the plate was incubated at room temperature for 30 min. The plate was then developed by adding 100 µl of freshly mixed TMB Substrate Solution to each well and incubating the plate in the dark for 10-15 min, followed by the addition of 100 µl of Stop Solution to each well. Plates were read at 450 nm within 30 min. Concentrations were calculated, and data are shown as the means of triplicate determinations.
IL-32 immunoblot analysis.
Extracted cellular proteins were fractionated and transferred onto nitrocellulose membranes by electroblotting. After blocking in 5% milk in TBS supplemented with 0.05% Tween 20 (TBST) for 1 h at room temperature, the membranes were incubated with purified mouse anti-human IL-32αβδγ antibody IgG 1 , κ (1:1,000 dilution; clone KU32-52, BioLegend) overnight at 4 °C in 5% milk in TBST. The membranes were washed with TBST and then incubated with a 1:1,000 dilution of HRP-conjugated goat anti-mouse polyclonal secondary antibody (Cell Signaling Technology) for 1 h at room temperature. After washing with TBS, antibody binding was visualized using enhanced chemiluminescence (SuperSignal West Pico Chemiluminescence Substrate, Thermo Fisher Scientific). Equivalent loading of proteins in each well was confirmed by Ponceau staining and actin control.
